Glenmark's arm IGI Therapeutics signs a $700 million licensing deal with AbbVie for its cancer drug ISB 2001, with potential ...

CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

Lilly and Incyte may face competition in the not-too-distant future however, as Pfizer has already reported positive results in the pivotal ALLEGRO trial of its JAK3 inhibitor ritlecitinib in ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The stock's fall snapped a three-day winning streak.

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

Investors are digesting Trump's stiff tariffs on imports from more than a dozen countries and delayed the return of sweeping ...

Global active pharmaceutical ingredients (API) market will reach $ 386.2 billion by 2032, growing by 6.4% annually over 2022-2032, driven by rising adoption of biologics in disease management, ...